利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

124 条记录 (耗时 0.028 秒)

    DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP
    1.
    发明申请
    DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP 审中-公开
    异位心脏病风险组的诊断代理

    公开(公告)号：US20130310321A1

    公开(公告)日：2013-11-21

    申请号：US13953273

    申请日：2013-07-29

    申请人： Masao Daimon ,  DAIICHI PURE CHEMICALS CO., LTD.

    发明人： Masao DAIMON ,  Tohru Minamino ,  Kenji Hashimoto ,  Issei Komuro

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  A61K38/185 ,  G01N33/74 ,  G01N2800/324

    摘要： The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.

    摘要翻译： 本发明涉及用于通过测定脑源性神经营养因子而进行的缺血性心脏病风险组的测定方法，其特征在于，包括抗脑源性神经营养因子抗体作为有效成分的缺血性心脏病危险性组的诊断剂 血液中的浓度，以及用于局部缺血性心脏病的抑制/预防药物，特别是用于梗塞后心肌重建的抑制/预防药物，其包含脑源性神经营养因子。

    D-AMINOACYLASE
    3.
    发明申请
    D-AMINOACYLASE 审中-公开
    D-氨基酸

    公开(公告)号：US20120149071A1

    公开(公告)日：2012-06-14

    申请号：US13345399

    申请日：2012-01-06

    申请人： Kimiyasu Isobe ,  Seiki Yamaguchi

    发明人： Kimiyasu Isobe ,  Seiki Yamaguchi

    IPC分类号： C12N9/80 ,  C12N1/20 ,  C12P13/04 ,  C12N1/21 ,  C12N15/55 ,  C12N15/74

    CPC分类号： C12N9/80

    摘要： A D-aminoacylase having a high substrate specificity is provided. This D-aminoacylase can produce D-amino acids from N-acetyl-D,L-amino acids conveniently and efficiently at a low cost.A D-aminoacylase produced by a microorganism of genus Defluvibacter; which acts on a N-acetyl-D-amino acid; which has a molecular weight (as determined by electrophoresis) of about 55,000 daltons, and an isoelectric point (as determined by two-dimensional electrophoresis for denatured system) of 5.3; which acts on N-acetyl-D-valine, N-acetyl-D-leucine, and the like, but not on N-acetyl-L-valine, N-acetyl-L-leucine, and the like; which has an optimal temperature of 37° C. (pH 8) and an optimal pH value of 8 to 8.5 at 37° C.; and whose activity is inhibited by Mn2+, Co2+, Ni2+, and Zn2+ each at 1 mmol/L, and by dithiothreitol, 2-mercaptoethanol, o-phenanthroline, and L-cysteine each at 5 mmol/L.

    摘要翻译： 提供了具有高底物特异性的D-氨基酸酰化酶。 该D-氨基酸酶可以以低成本方便且有效地从N-乙酰基-D，L-氨基酸产生D-氨基酸。 由去纤维杆菌属的微生物产生的D-氨基酸酰化酶; 其作用于N-乙酰基-D-氨基酸; 其具有约55,000道尔顿的分子量（通过电泳测定）和5.3的等电点（通过用于变性体系的二维电泳测定）; 其作用于N-乙酰基-D-缬氨酸，N-乙酰基-D-亮氨酸等，但不适用于N-乙酰基-L-缬氨酸，N-乙酰基-L-亮氨酸等; 其最适温度为37℃（pH8），最适pH值为8〜8.5，在37℃下。 Mn2 +，Co2 +，Ni2 +和Zn2 +各自以1 mmol / L的速度抑制其活性，二硫苏糖醇，2-巯基乙醇，邻菲咯啉和L-半胱氨酸各自以5 mmol / L的速度进行抑制。

    METHOD FOR MEASURING HYPOCHLORITE ION
    6.
    发明申请
    METHOD FOR MEASURING HYPOCHLORITE ION 审中-公开
    测量高碘离子的方法

    公开(公告)号：US20090263910A1

    公开(公告)日：2009-10-22

    申请号：US12493995

    申请日：2009-06-29

    申请人： Ken-Ichi Setsukinai ,  Yasuteru Urano ,  Tetsuo Nagano

    发明人： Ken-Ichi Setsukinai ,  Yasuteru Urano ,  Tetsuo Nagano

    IPC分类号： G01N33/00

    CPC分类号： G01N21/6428 ,  G01N2021/7786 ,  Y10T436/14 ,  Y10T436/19 ,  Y10T436/196666 ,  Y10T436/200833

    摘要： A method for measuring hypochlorite ion, which comprises the steps of:(A) reacting, with hypochlorite ion, a compound represented by the following general formula (I): wherein R1 represents a 2-carboxyphenyl group which may be substituted; R2 represents a phenyl group which is substituted with a substituted or unsubstituted amino group; X1 and X2 each independently represents either hydrogen atom or a halogen atom; or a salt thereof; and (B) measuring fluorescence of a dearylated compound generated in the aforementioned step (A) or a salt thereof.

    摘要翻译： 一种测定次氯酸根离子的方法，包括以下步骤：（A）与次氯酸根离子反应由以下通式（I）表示的化合物：其中R1表示可被取代的2-羧基苯基; R2表示被取代或未取代的氨基取代的苯基; X1和X2各自独立地表示氢原子或卤素原子; 或其盐; 和（B）测量在上述步骤（A）中产生的脱芳基化合物的荧光或其盐。

    Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme
    7.
    发明申请
    Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme 审中-公开
    估计由施用化合物引起的药物不良反应的风险的方法，所述化合物本身由UGT1A1酶代谢或其代谢中间体被酶代谢

    公开(公告)号：US20090263818A1

    公开(公告)日：2009-10-22

    申请号：US12453291

    申请日：2009-05-06

    申请人： Yoshinori Hasegawa ,  Yu-uichi Ando ,  Kaoru Shimokata

    发明人： Yoshinori Hasegawa ,  Yu-uichi Ando ,  Kaoru Shimokata

    IPC分类号： C12Q1/68

    CPC分类号： C12N9/1051 ,  C12Q1/6876 ,  C12Q2600/156

    摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.

    摘要翻译： 评价由伊立替康的给药引起的药物不良反应的风险的评价方法以及减少由伊立替康给药引起的不良药物反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不利的drub反应的表达风险，为个体患者设计了伊立替康的给药剂量，从而减少了施用伊立替康引起的不良药物反应。

    Fluorescent probe
    8.
    发明授权
    Fluorescent probe 有权
    荧光探针

    公开(公告)号：US07524974B2

    公开(公告)日：2009-04-28

    申请号：US10519682

    申请日：2003-07-07

    申请人： Tetsuo Nagano ,  Yasuteru Urano ,  Suguru Kenmoku ,  Kohjiro Kanda

    发明人： Tetsuo Nagano ,  Yasuteru Urano ,  Suguru Kenmoku ,  Kohjiro Kanda

    IPC分类号： C07D311/90

    CPC分类号： G01N27/44726 ,  C07D311/82 ,  C09B11/06 ,  C09B11/245 ,  G01N31/22

    摘要： A fluorescent probe which is represented by the following formula (I): (wherein, R1 and R2 represent hydrogen atom, or a substituent for trapping proton, a metal ion, or an active oxygen species, or the like; R3 represents a monovalent substituent; R4 and R5 represent hydrogen atom or a halogen atom; R6 represents hydrogen atom, an alkylcarbonyl group, or an alkylcarbonyloxymethyl group, provided that a combination of R1, R2, and R3 provides (1) substantially high electron density of the benzene ring to which said groups bind, so that the compound represented by the formula (I) is substantially no fluorescent before the trapping of proton, or the like, and (2) substantially reduced electron density of the benzene ring to which said groups bind, so that a compound after the trapping, which is derived from the compound represented by the formula (I) is substantially highly fluorescent after the trapping of proton or the like). A fluorescent probe having an excellent fluorescence property is provided.

    摘要翻译： 由下式（I）表示的荧光探针：（其中，R1和R2表示氢原子，或用于捕获质子的取代基，金属离子或活性氧等）; R3表示一价取代基 R 4和R 5表示氢原子或卤素原子; R 6表示氢原子，烷基羰基或烷基羰氧基甲基，条件是R 1，R 2和R 3的组合提供（1）苯环的电子密度基本上高到 所述基团结合，使得由式（I）表示的化合物在捕获质子之前基本上不发荧光等，和（2）所述基团所结合的苯环的电子密度基本上降低，使得 衍生自由式（I）表示的化合物捕获后的化合物在质子等的捕获之后基本上是高度荧光的）。 提供具有优异荧光性能的荧光探针。

    METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS
    9.
    发明申请
    METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS 审中-公开
    定量测定低密度脂蛋白胆固醇的方法

    公开(公告)号：US20090075310A1

    公开(公告)日：2009-03-19

    申请号：US12265202

    申请日：2008-11-05

    申请人： Mitsuhiro NAKAMURA ,  Kazuo NAKANISHI ,  Koichi HINO ,  Mitsuhisa MANABE

    发明人： Mitsuhiro NAKAMURA ,  Kazuo NAKANISHI ,  Koichi HINO ,  Mitsuhisa MANABE

    IPC分类号： C12Q1/60

    CPC分类号： C12Q1/60

    摘要： A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholesterols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers.

    摘要翻译： 一种定量测定LDL胆固醇的方法，包括以下步骤：向血清中加入选自聚氧乙烯亚烷基苯基醚和聚氧乙烯亚烷基三苄基苯基醚的表面活性剂和胆固醇分析酶试剂，以便优先反应高密度和非常低密度的胆固醇中的胆固醇 在脂蛋白中，然后确定其后反应的胆固醇的量。 该方法可以消除离心和电泳等预处理的必要性，能够以高效，简单的方式进行定量测定，可以应用于各种自动分析装置。